This is a working overview of drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-21. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
== External links == The Bülow case at www.crimelibrary.com Clarendon Court Mansion, Bülow's former home Obituary in the Star Gazette National Center for Victims of Crime (formerly the Sunny Von Bulow National Victim Advocacy Center)
Ethel and Howard Florey published the results of clinical trials of penicillin in The Lancet on 27 March 1943, reporting the treatment of 187 cases of sepsis with penicillin. It was upon this medical evidence that the British War Cabinet set up the Penicillin Committee on 5 April 1943. The committee consisted of Cecil Weir, Director General of Equipment, as chairman; Alexander Fleming; Howard Florey; V. D. Allison, another one of Fleming's former research students; Sir Percival Hartley, the head of the MRC; and representatives from pharmaceutical companies. This led to the mass production of penicillin by the next year.
Stoney River Steakhouse & Grill is a chain of steakhouses in the United States. In 2008, the company had 12 locations. As of 2025, there are ten Stoney River restaurants. In 2007, O'Charley's filed a lawsuit against competitor Darden claiming their Rocky River Grillhouse restaurant was too similar of a trademark to their Stoney River Legendary Steaks brand.
=== Investigations === Several sets of investigations, both congressional via the Senate Armed Services Committee, military via courts-martial, and criminal for non-military contractors, were launched in response to the scandal. Seymour Hersh, who exposed the Abu Ghraib scandal, and reports in Newsweek, has taken the case even further. In 2003, Donald Rumsfeld instituted a policy that "encouraged physical coercion and sexual humiliation of Iraqi prisoners in an effort to generate more intelligence about the growing insurgency in Iraq.". This policy stemmed from an earlier policy taken toward al-Qaeda prisoners. A memo to the Bush White House from counsel Alberto Gonzales claimed that the new sort of war renders the Geneva Conventions' limitations on interrogating enemy prisoners "obsolete". The program was approved by the CIA, NSA, and the National Security Council. President George W. Bush was informed of it. The Under Secretary of Defense for Intelligence Steven Cambone administered the operation. His deputy, William Boykin, instructed the head of operations at Camp X-ray Maj. Gen. Geoffrey Miller to do the same at Abu Ghraib. Miller told Brig. Gen. Janis Karpinski that the prison would now be dedicated to gathering intelligence. Douglas Feith and William Haynes were also involved in the operation. On May 18, 2004, a military intelligence analyst named Samuel Provance came out to the press, stating "There's definitely a cover-up".
Sources: en.wikipedia.org
As in other X-linked diseases, males are affected because they only have one copy of the X chromosome. In Lesch–Nyhan syndrome, the defective gene is that for hypoxanthine-guanine phosphoribosyltransferase (HGPRT), a participant in the 'recycling' of purine nucleotides. Female carriers have a second X chromosome, which contains a "normal" copy of HPRT, preventing the disease from developing, though they may have increased risk of hyperuricemia. A large number of mutations of HPRT are known. Mutations that only mildly decrease the enzyme's function do not normally cause the severe form of LNS, but do produce a milder form of the disease which still features purine overproduction accompanied by susceptibility to gout and uric acid nephrolithiasis. Formation of DNA (during cell division) requires nucleotides, molecules that are the building blocks for DNA. The purine bases (adenine and guanine) and pyrimidine bases (thymine and cytosine) are bound to deoxyribose and phosphate and incorporated as necessary. Normally, the nucleotides are synthesized de novo from amino acids and other precursors. A small part, however, is 'recycled' from degraded DNA of broken-down cells. This is termed the "salvage pathway". HGPRT is the "salvage enzyme" for the purines: it channels hypoxanthine and guanine back into DNA synthesis. Failure of this enzyme has two results:
== Early life, education, and career == Wittman was born in Washington, D.C., the son of adoptive parents Regina C. (née Wood) and Frank Joseph Wittman. His father was of German descent and his mother's ancestors included immigrants from Ireland and Canada. He grew up in Henrico County, Virginia. He attended the Virginia Polytechnic Institute and State University (Virginia Tech) as a member of the Corps of Cadets and Army ROTC and studied biology. While at Virginia Tech, he spent the summers working at a tomato cannery and on a fishing vessel. Also while in college, Wittman was a member of the Delta Tau Delta fraternity. He earned a master's degree in public health from the University of North Carolina at Chapel Hill in 1990 and a Ph.D. from Virginia Commonwealth University in 2002. Wittman worked for 20 years with the Virginia Department of Health. He served as an environmental health specialist and was field director for the Division of Shellfish Sanitation. Wittman served on the Montross Town Council from 1986 to 1996 and as mayor of the Town of Montross from 1992 to 1996. Two of his major initiatives in this office were the overhaul of the sewage system and the development of a computerized system for tax billing. From 1996 to 2005, Wittman served on the Westmoreland County Board of Supervisors, the last two years as chair. He helped create new libraries and pushed for raises in teacher salaries.
== Clinical importance == S. haemolyticus is the second-most clinically isolated CoNS (S. epidermidis is the first) and it is considered an important nosocomial pathogen. Human infections include: native valve endocarditis, sepsis, peritonitis, and urinary tract, wound, bone, and joint infections. Infrequent soft-tissue infections usually occur in immunocompromised patients. Like other CoNS, S. haemolyticus is often associated with the insertion of foreign bodies, such as prosthetic valves, cerebrospinal fluid shunts, orthopedic prostheses, and intravascular, urinary, and dialysis catheters. S. haemolyticus is multi-drug resistant and able to form biofilms, which makes infections especially difficult to treat.
=== Tolerance === Mescaline is associated with rapid tolerance development, including cross-tolerance with other psychedelics like LSD and psilocybin. This tolerance is apparent within a few days and resets after 3 or 4 days of abstinence.
By the early 1980s, genes for these interferons had been cloned, adding further definitive proof that interferons were responsible for interfering with viral replication. Gene cloning also confirmed that IFN-α was encoded by a family of many related genes. The type II IFN (IFN-γ) gene was also isolated around this time. Interferon was first synthesized manually at Rockefeller University in the lab of Dr. Bruce Merrifield, using solid phase peptide synthesis, one amino acid at a time. He later won the Nobel Prize in chemistry. Interferon was scarce and expensive until 1980, when the interferon gene was inserted into bacteria using recombinant DNA technology, allowing mass cultivation and purification from bacterial cultures or derived from yeasts. Interferon can also be produced by recombinant mammalian cells. Before the early 1970s, large scale production of human interferon had been pioneered by Kari Cantell. He produced large amounts of human alpha interferon from large quantities of human white blood cells collected by the Finnish Blood Bank. Large amounts of human beta interferon were made by superinducing the beta interferon gene in human fibroblast cells. Cantell's and Tan's methods of making large amounts of natural interferon were critical for chemical characterisation, clinical trials and the preparation of small amounts of interferon messenger RNA to clone the human alpha and beta interferon genes. The superinduced human beta interferon messenger RNA was prepared by Tan's lab for Cetus.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.